Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
LIVE TV DownloadNews18 App
»
1-min read

India's Antitrust Watchdog Orders Probe Into Roche Cancer Drug

Country's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

Reuters

Updated:April 26, 2017, 10:57 PM IST
facebookTwitterskypewhatsapp
India's Antitrust Watchdog Orders Probe Into Roche Cancer Drug
In this file photo, Roche tablets are seen positioned in front of a displayed Roche logo in this picture illustration. (Photo: Reuters)
Loading...

Mumbai: Country's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 percent discount to the original.

India's Biocon and US firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.

India, with among the highest number of cancer patients in the world, is a big market for trastuzumab, which is indicated to treat certain forms of breast and gastric cancer.

Roche first launched the drug in India in 2002 and sells it for about 75,000 rupees ($1,170) for a 440 mg vial.

In an interim order released on Tuesday, the CCI said it found merit in Biocon and Mylan's arguments, and ordered its director general to conduct a "detailed investigation" and submit a report within 60 days.

"Roche adheres to all applicable laws and regulations in countries where it operates," Roche spokeswoman Shilpika Das said in a statement. "We are fully committed to cooperating with the authorities in India."

Biocon said it welcomed the CCI's order, which although not final, but the investigation could result in penalties, a lawyer at the Delhi High Court, who declined to be named, said.

Roche, which has been engaged in a legal tussle with Biocon and Mylan since 2014, has the option of filing a petition to contest the order, the lawyer added.

In their complaint, Biocon and Mylan allege Roche wrote to doctors, hospitals, and state and federal regulators, misleading them about the safety of efficacy of the biosimilar versions.

"When seen collectively in the background of surrounding facts and circumstances, they only appear to be a part of the bigger plan/strategy of Roche Group to eliminate competition posed by biosimilars to Roche’s products in the relevant market," the CCI said in its order, made public on Tuesday.

| Edited by: Bijaya Das
Read full article
Loading...
Next Story
Next Story

Also Watch

facebookTwitterskypewhatsapp
Most Active
Company Price Change %Gain
M&M Financial 305.30 -10.25
Yes Bank 91.75 1.21
Larsen 1,407.70 -0.13
Zee Entertain 364.55 1.04
HDFC 2,177.00 1.80
Company Price Change %Gain
M&M Financial 304.65 -10.44
Yes Bank 91.75 1.16
Bharti Infratel 261.55 -0.10
HDFC Life 524.10 3.05
Zee Entertain 364.00 0.84
Top Gainers
Company Price Change %Gain
HDFC 2,170.25 1.48
Yes Bank 91.65 1.10
Power Grid Corp 212.45 0.95
Zee Entertain 364.45 1.01
Tech Mahindra 674.30 0.46
Company Price Change %Gain
HDFC 2,178.00 1.89
Yes Bank 91.65 1.05
Power Grid Corp 212.35 0.93
Asian Paints 1,435.25 0.48
HDFC Bank 2,263.95 -1.44
Top Losers
Company Price Change %Gain
BPCL 346.90 -3.38
Eicher Motors 16,682.45 -2.43
Vedanta 164.45 -2.17
JSW Steel 258.45 -1.84
Hindalco 199.75 -1.65
Company Price Change %Gain
Vedanta 168.05 0.48
M&M 556.85 -0.82
Maruti Suzuki 5,790.00 -1.45
Bajaj Auto 2,489.30 -1.41
Bharti Airtel 339.35 -1.27

Live TV

Loading...
Countdown To Elections Results
To Assembly Elections 2018 Results